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Abstract: In Asian countries, ultrasound has been proposed as a possible alternative for mammography
in breast cancer screening because of its superiority in dense breasts, accessibility and low costs. This
research aimed to meta-analyze the evidence for the diagnostic performance of ultrasound compared
to mammography for breast cancer screening in Asian women. PubMed, Web of Science, and China
National Knowledge Infrastructure databases were searched for studies that concurrently compared
mammography and ultrasound in 2000–2019. Data extraction and risk of bias were performed
according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
(PRISMA) statement. The primary outcome was the sensitivity and specificity. Bivariate random
models were used to generate pooled estimates of diagnostic parameters and 95% confidence intervals
(95% CI). In total, 4424 studies were identified of which six studies met the inclusion criteria with a
sample size of 124,425 women. The pooled mean prevalence of the included studies was 3.7‰ (range:
1.2–5.7‰). The pooled sensitivity of mammography was significantly higher than that of ultrasound
(0.81 [95% CI 0.71–0.88] versus 0.65 [95% CI 0.58–0.72], p = 0.03), but no significant differences were
found in specificity (0.98 [95% CI: 0.94–1.00] versus 0.99 [95% CI: 0.97–1.00], p = 0.65). In conclusion,
based on the currently available data on sensitivity alone, there is no indication that ultrasound can
replace mammography in breast cancer screening in Asian women.
Keywords: breast neoplasms; mass screening; meta-analysis; mammography; ultrasonography
1. Introduction
Breast cancer is nowadays the main cause of cancer-related death in Asian women, with a dramatic
increase in age-standardized incidence over recent years [1,2]. Data from China, South Korea, and
Singapore showed that, during the period from 1988 to 2009, the estimated annual increase of the
age-standardized incidence ranged from 2.0% to 6.4% [3]. In 2012, more than 600,000 new breast cancer
cases were reported in Asia, accounting for 39% of all diagnosed breast cancers worldwide [2].
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Currently, there is no universally effective method to lower the incidence of breast cancer [4,5].
However, regular screening could reduce disease burden as more cancers could be detected at earlier
stages, allowing for better treatment and survival [6]. Although controversies about the efficiency
of breast cancer screening still exist, several successful organized screening programs introduced in
European and North American countries have shown that breast cancer mortality can be reduced by
20% by regular mammography screening for women aged 50 to 69 years [7–9].
Several Asian countries, such as Japan, Korea, and Singapore, have also organized breast cancer
screening programs using mammography as the main screening modality [10–12]. However, whether
the typical mammography-based screening programs in western countries could also be efficient in
an Asian population in terms of early diagnosis, mortality reduction, and cost-effectiveness is still
unclear. Asian women tend to have smaller and more dense breasts compared to Western women,
and the mean onset age of breast cancer for Asian women is around 40–50 years, which is 10 years
younger than that for Western women [13–15]. Moreover, the sensitivity of mammography correlates
negatively with breast density and is especially limited in younger women [16]. In addition, the costs
and accessibility of mammography are important issues for many Asian countries with relatively
limited medical resources [2,17]. Therefore, mammography-based screening in Asian women may not
be as efficient as in Western women, and ultrasound has been proposed as a possible, more favorable
alternative [2].
Compared with mammography, ultrasound is a cheaper, radiation-free, and less strenuous
modality. Studies have shown that adjunctive ultrasound could detect additional cancers in women
with negative mammograms and that it typically outperforms mammography in women with
dense breast tissue [18,19]. However, whether ultrasound could serve as an accurate modality for
breast cancer screening in Asian women is unclear. Therefore, we aimed to compare the diagnostic
performance of ultrasound with mammography as a breast cancer screening modality in Asian women
by a meta-analysis.
2. Materials and Methods
This systematic review and meta-analysis was performed according to the Preferred Reporting
Items for Systematic Review and Meta-Analysis Protocols (PRISMA) statement [20] and the Cochrane
Handbook for Systematic Reviews of Diagnostic Test Accuracy (version 1.0.0, 2013) [21]. The PROSPERO
registration number of this study was CRD42017070617.
2.1. Search Strategy and Selection Criteria
A literature search was conducted for studies published between 1 January 2000 and 31 December
2019. PubMed, Web of Science, and China National Knowledge Infrastructure databases were
searched with the following keywords: “breast neoplasms”, “breast cancer”, “mass screening”,
“ultrasound”, “radiography”, “mammography”, and “Asia”. Study titles, abstracts, and texts were
screened independently by two authors (J.W. and L.D.). An example of the search strategy in PubMed
can be found in Table S1. Disagreements between the two authors were resolved by consensus with a
third author (W.L.). All searches were supplemented by checking the references of the identified articles.
2.2. Inclusion Criteria
Studies were included if they met the following criteria: (I) original study; (II) participants
were Asian women who live in Asian countries and were not diagnosed with breast cancer before;
(III) population-wide breast cancer screening; (IV) the study had a concurrent design that compared
mammography and ultrasound at the same time; and (V) the diagnostic standard included biopsy
with follow-up results.
2.3. Data Extraction
Data were extracted independently by two authors (J.W. and S.Z.) and listed in a standardized
extraction table including: author names, year of publication, study design, country, starting age of
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screening, breast cancer risk, follow-up length, screening interval (years), sample size, publication type,
program duration, participation rate, and the numbers of true positives, false positives, false negatives,
and true negatives.
2.4. Quality Assessment
Two authors (J.W. and S.Z.) used the Revised Tool for Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) as recommended by the Cochrane Handbook for Systematic Reviews of Diagnostic
Test Accuracy [22]. Disagreements on the risk of bias were resolved by group discussion with other
authors. The risk of bias and concerns about the relevance of each study were rated as “low” or “high”;
in addition, studies were rated as “unclear” if there was insufficient information to make a judgement.
2.5. Data Analysis
As heterogeneity was expected to be high in the meta-analysis of diagnostic test accuracy studies,
a bivariate random model was used to estimate the pooled estimates of sensitivity, specificity, and
diagnostic odds ratios (DORs) with 95% confidence intervals (95% CI) [23]. The DOR summarizes the
diagnostic accuracy of the test as a single indicator that describes how many times higher the odds are
of obtaining a test positive result in a diseased rather than a non-diseased person [23]. The value of a
DOR ranges from 0 to infinity, with a higher value suggesting a better test performance [24]. Sensitivity
was the main outcome of our study. To evaluate whether the pooled sensitivity and specificity of both
modalities differed, the model was expanded by adding a modality-type covariate [25], and likelihood
ratio tests were used to test significance. To assess the sensitivity and specificity of mammography and
ultrasound separately, forest plots were used.
All analyses used two-sided tests and a significance level of 0.05. Statistical analyses were performed
by Stata/SE 15.0 (StataCorp, College Station, TX, USA), and RevMan (Version 5.3 Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used to display the results graphically.
3. Results
3.1. Studies Characteristics
Our search returned 2689 English and 1735 Chinese records, six of which met the inclusion criteria
(Figure 1). Table 1 details the characteristics of the included studies. We identified two multicenter
randomized controlled trials (RCT) and four cohort studies (Table 1) [26–31]. The diagnostic accuracy
data for the included studies is summarized in Table 2. The screening durations ranged from 24 to
87 months. Follow-up time varied among studies, ranging from 12 months to 24 months. Two studies
used digital mammography [26,30]; two studies used screen-film mammography [27,29]; and the other
two studies did not specify the type of mammography [28,31].













Ohuchi [26] 2016 RCT Japan 40 High 2.0
Honjo [27] 2007 Cohort Japan 30 Average 1.0
Zhou [28] 2012 Cohort China 35 High 0.5–0.8
Kang [29] 2014 Cohort China 35 Average 1.0
Shen [30] 2015 RCT China 30 High 1.0
Dong [31] 2018 Cohort China 45 Average 1.0
Abbreviations: RCT = Randomized clinical trial.
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TP (%) FP (%) FN (%) TN (%) PPV(%)
NPV
(%)
Ohuchi [26] US 36,049 5.6 (4.9–6.4) 143 (0.4) 2289 (6.3) 59 (0.2) 33,558 (93.1) 5.9 99.8
MG 35,130 4.3 (3.7–5.1) 109 (0.3) 2576 (7.3) 43 (0.1) 32,402 (92.2) 4.1 99.9
Honjo [27] US 3453 3.8 (2.0–6.4) 7 (0.2) 158 (4.6) 6 (0.2) 3282 (95.0) 4.2 99.8
MG 3453 3.8 (2.0–6.4) 8 (0.2) 271 (7.8) 5 (0.2) 3169 (91.8) 2.9 99.8
Zhou [28] US 7017 4.3 (2.9–6.1) 22 (0.3) 72 (1.0) 8 (0.1) 6915 (98.6) 23.4 99.9
MG 7020 4.3 (2.9–6.1) 26 (0.4) 220 (3.1) 4 (0.1) 6770 (96.4) 10.6 99.9
Kang [29] US 2471 5.7 (3.1–9.5) 9 (0.4) 9 (0.4) 5 (0.2) 2448 (99.0) 50.0 99.8
MG 2471 5.7 (3.1–9.5) 11 (0.5) 24 (1.0) 3 (0.1) 2433 (98.4) 31.4 99.9
Shen [30] US 4214 2.6 (1.3–4.7) 7 (0.2) 3 (0.1) 4 (0.1) 4200 (99.6) 70.0 99.9
MG 4170 1.2 (0.4–2.8) 3 (0.1) 1 (0.0) 2 (0.1) 4164 (99.8) 75.0 99.9
Dong [31] US 31,918 3.1 (2.5–3.8) 61 (0.2) 389 (1.2) 38 (0.1) 31,430 (98.5) 13.6 99.9
MG 31,918 3.1 (2.5–3.8) 84 (0.3) 604 (1.9) 15 (0.1) 31,215 (97.7) 12.2 99.9
Abbreviations: MG = Mammography; US = Ultrasound; CI = Confidence interval; TP = True positive; FP =
False negative; FN = False negative; TN = True negative; PPV = Positive predictive value; NPV = Negative
predictive value.
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Figure 1. Flow chart of the literature search.
3.2. Quality Assessment
The results of the QUADAS-2 assessment are presented in Figure 2. Concerning participant
selection in the six included studies, the risk of bias in participant selection was high in one study and
low in the remaining five studies (Figure 2). In two studies, the risk of bias was high and was mainly
related to the “Flow and Timing” domain.
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4. Discussion
In this meta-analysis, we found that the pooled sensitivity of mammography was significantly
higher than the pooled sensitivity of ultrasound in Asian women (0.81 [95% CI 0.71–0.88] versus 0.65
[95% CI 0.58–0.72], p = 0.03). However, no significant differences were found in specificity between
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both modalities. Although there was a high degree of heterogeneity in the included studies, potential
sources of heterogeneity could not be explored because of limited data.
Ultrasound has been proposed as a possible alternative to mammography in Asian countries,
which is supported by studies showing a trend that screening with ultrasound has a higher sensitivity
compared with mammography in Asian women [32–35]. However, the evaluation of the design of
these studies shows that these studies only evaluated one screening modality (either mammography
or ultrasound). As such, these studies are more prone to bias, and it can be expected that these studies
present more favorable results regarding the modality under study. In our study, we included only
studies that performed a concurrent analysis of breast screening with ultrasound and mammography,
and we did not find that mammography could be replaced by ultrasound in terms of sensitivity.
The main reason why ultrasound was proposed as a possible alternative to mammography in Asian
countries is its superior performance in younger women and women with dense breasts. Currently, there
are debates about differences in peak onset age and breast density in Asian and Western women [13].
Though some studies have shown that the peak onset age in Asian women is around 40–50 years, which
is at least 10 years earlier than in Western women [36,37], other studies have argued that the earlier peak
age in Asian women is a transient phenomenon during a westernizing process as the peak onset age
in Japan, Korea, and urban China has increased and is now comparable to western countries [38–40].
In addition, there are conflicting reports about ethnicity differences in breast density. Rajaram et al.,
for example, found that mammographic density was significantly higher in Asian women than in
Caucasian women [15]. By contrast, several studies showed that higher breast density in Asian women
is associated with breast size and body mass index rather than ethnicity differences [14,41].
In some Asian countries, such as Japan and China, ultrasound has been recommended as an
adjunct modality to mammography in breast cancer screening [26,42]. Several studies have shown that
ultrasound could improve cancer detection in women at a younger age and in women with dense breasts
and negative mammogram results [26,43]. For example, the Japan Strategic Anti-cancer Randomized
Trial (J-START), one of the largest randomized clinical trials that used adjunctive ultrasound as a
screening modality in Asian women, showed that mammography plus ultrasound had a higher
sensitivity and a higher cancer detection rate compared to mammography alone in women aged 40–49
(sensitivity: 91% vs. 77%; cancer detection rate: 0.50% vs. 0.32%, respectively) [26]. In addition, a
meta-analysis focusing on women with dense breasts and negative mammography results showed that
adjunctive ultrasound screening resulted in a 40% average increase of the cancer detection rate [43].
However, whether ultrasound improves cancer detection remains controversial. A recent retrospective
analysis of the Breast Cancer Surveillance Consortium (BCSC) showed that, for the general population,
the cancer detection rates were similar for mammography plus ultrasound and mammography alone
(5.4 vs. 5.5 per 1000 screens, respectively), albeit with a higher false-positive rate in the mammography
plus ultrasound group (55 vs. 22 per 1000, respectively) [44].
The estimation of sensitivity and specificity can be influenced by population characteristics and
study design. Based on our analysis, the pooled sensitivity of mammography in the Asian population
was 81%, which was relatively lower than 87% in a US population [45]. In most of the included
studies, the starting age of screening was around 30–35 years, which was much younger than in
other breast screening programs [7–9]. This can result in lower estimations for both sensitivity and
specificity [16,34,46]. Secondly, most of the included studies were screening trials in which only the
results of the first round were reported. This can result in an overestimation of sensitivity as prevalent
cancers could also be detected by screening in the first round [47]. Thirdly, almost all studies applied a
short follow-up time of one year, except the study of Ohuchi et al. [26], which might lead to a higher
pooled specificity as the number of true negatives was overestimated [48]. In this analysis, although
the sensitivity of ultrasound is relatively low (65%), the pooled specificity of ultrasound reached an
unrealistically high value of 99%. We considered that the short follow-up time might be one of the
possible reasons for such a high specificity.
There are some limitations of this study. Firstly, as only a few studies reported data regarding
interval cancers and as varied screening intervals were applied, we were not able to perform a
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quantitative analysis on interval cancers. Secondly, the risk of bias was highest in the flow and timing
domain, primarily because of reduced participation and loss to follow-up, and the pooled sensitivity
estimates may, therefore, have been slightly overestimated. Thirdly, there are only a few screening
programs that use ultrasound as the routine screening method, and only six studies could be included,
with four from China. Thus, the results for ultrasound need careful consideration when extrapolating
to other Asian countries. Lastly, although the heterogeneity was expected to be high in this type
of meta-analysis, there were too few studies included to perform adequate subgroup analyses, and,
therefore, potential sources of heterogeneity could not be explored.
5. Conclusions
Based on the current sensitivity data, there is no indication that ultrasound can replace mammography
in breast cancer screening in Asian women. However, whether mammography screening should be
recommended in Asian countries needs careful consideration. Future research on the long-term outcome
is required and should be accompanied by an assessment of the cost-effectiveness of mammography
screening in Asian settings.
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